$ORKA News

Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target

Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target

Oruka Therapeutics Stock Gets A Lift From Psoriasis Trial Results

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Oruka’s Psoriasis Treatment Could Generate $7B In Peak Sales, Says Guggenheim – ORKA Stock Heads For Best Day In Over 4 Months

Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis - Slideshow

Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript

Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial

Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis

Oruka Reports Week 16 Phase 2b Results For ORKA-001 In Plaque Psoriasis, With 61% PASI 100 And 86% PASI 90 Response Rates; ORKA-001 On Track To Advance Into Phase 3 Trials In 1H 2027

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

Oruka Therapeutics (ORKA) Stock May Be Trading On A Rich Premium To Book Value

BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End

Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders

Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy

Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data